Evotec-Secarna: new partnership in antisense oligonucleotide-based therapeutics The German companies Evotec and Secarna Pharmaceuticals have concluded a strategic partnership in the field of antisense oligonucleotide (ASO)-based therapeutics. Secarna, a global leader in discovering and developing next-generation ASO, combines its proprietary LNAplus™ platform with cutting edge third generation LNA-chemistry to generate…..
HexaPro: a new tool to speed up Covid-19 vaccine production ? Most coronavirus vaccine candidates train the human immune system to recognize the spike protein on the surface of the SARS-CoV-2 virus in order to fight infection. A scientific team at The University of Texas at Austin has successfully redesigned…..